Expression of NF-κB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions

Table 1 Expression of NF-κBp65 protein, hTERT mRNA and protein in precancerous lesions and gastric cancer

Lesion	Cases	NF-κBp65				hTERT mRNA				hTERT protein
		+	++	+++	Total (%)	+	++	+++	Total (%)	+	++	+++	Total (%)
Normal	10	0	0	0	0 (0)	1	0	0	1 (10.00)	0	0	0	0 (0)
Intestinal metaplasia	23	7	1	0	8 (34.78)b	6	3	0	9 (39.13)b	5	2	0	7 (30.43)b
Dysplasia	15	7	1	0	8 (53.33)a	7	3	0	10 (66.67)a	7	2	0	9 (60.00)a
Cancer	41	7	14	4	25 (60.98)a	6	20	9	35 (85.37)a	6	20	6	32 (78.05)a

^aP < 0.05, vs normal mucosa group;

^bP < 0.01, vs cancer group.

Table 2 Correlation between expression of NF-κBP65 protein, hTERT mRNA and protein and clinicopathological features

Factor	Cases	NF-κB	hTERT	hTERT
		P65 (%)	mRNA (%)	protein (%)
Gender
Male	30	16 (53.33)	24 (80.00)	24 (80.00)
Female	11	9 (81.82)	11 (100.00)	8 (72.73)
Age (years)
< 60	24	14 (58.33)	21 (87.50)	20 (83.33)
≥ 60	17	11 (64.71)	14 (82.35)	12 (70.59)
Histology (type)
Intestinal	16	7 (43.75)	12 (75.00)	10 (62.50)
Differentiation	25	18 (72.00)	23 (92.00)	22 (88.00)
Differentiation
Well	13	3 (23.08)b	9 (69.23)	7 (53.85)a
Poor	28	22 (78.57)	26 (92.86)	25 (89.29)
Lymph node metastasis
Negative	16	4 (25.00)b	12 (75.00)	9 (56.25)a
Positive	25	21 (84.00)	23 (92.00)	23 (92.00)
Stage
Early	12	2 (16.67)b	7 (58.33)b	5 (41.67)b
Advanced	29	23 (79.31)	28 (96.55)	27 (93.10)
Tumor size (cm)
< 5	19	6 (31.58)b	14 (73.68)	13 (68.42)
≥ 5	22	19 (86.36)	21 (95.45)	19 (86.36)
Depth of invasion
m, sm	10	2 (20.00)a	6 (60.00)	4 (40.00)a
ms, ss	17	11 (64.71)	16 (94.12)	15 (88.24)
se, si	14	12 (85.71)	13 (92.86)	13 (92.86)

^aP < 0.05,

^bP < 0.01, From comparison in each group of clinicopatho-logic feature by chi-square test or Fisher’s exact test. m: mucosa, sm: submucosa, mp: muscularis propria, ss: subserosa, se: inva-sion to serosa, si: invasion to other organ. Tumor size was de-fined as the largest size in extension on the gastric mucosa.